Nektar Therapeutics Valuation

ITH Stock  EUR 1.25  0.00  0.00%   
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Nektar Therapeutics last-minute Real Value cannot be determined due to lack of data. The latest price of Nektar Therapeutics is €1.25. Our model forecasts the value of Nektar Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 187.95 M, return on equity of -0.75, and Operating Margin of (3.29) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Undervalued
Today
1.25
Please note that Nektar Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Nektar Therapeutics is based on 3 months time horizon. Increasing Nektar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Nektar Therapeutics is useful when determining the fair value of the Nektar stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Nektar Therapeutics. Since Nektar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nektar Stock. However, Nektar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.25 Real  0.0 Hype  0.0 Naive  1.09
The real value of Nektar Stock, also known as its intrinsic value, is the underlying worth of Nektar Therapeutics Company, which is reflected in its stock price. It is based on Nektar Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Nektar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nektar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.00
Real Value
8.27
Upside
Estimating the potential upside or downside of Nektar Therapeutics helps investors to forecast how Nektar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nektar Therapeutics more accurately as focusing exclusively on Nektar Therapeutics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.460.961.47
Details
Hype
Prediction
LowEstimatedHigh
0.000.008.27
Details
Naive
Forecast
LowNext ValueHigh
0.021.099.36
Details

Nektar Therapeutics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Nektar Therapeutics's current stock value. Our valuation model uses many indicators to compare Nektar Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nektar Therapeutics competition to find correlations between indicators driving Nektar Therapeutics's intrinsic value. More Info.
Nektar Therapeutics is currently regarded as number one stock in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about  0.15  of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Nektar Therapeutics is roughly  6.60 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nektar Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nektar Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nektar Therapeutics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Nektar Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Nektar Therapeutics and how it compares across the competition.

About Nektar Therapeutics Valuation

The stock valuation mechanism determines the current worth of Nektar Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Nektar Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Nektar Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Nektar Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Nektar Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nektar Therapeutics. We calculate exposure to Nektar Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Nektar Therapeutics's related companies.
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California. NEKTAR THERAPEUTICS operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 618 people.

8 Steps to conduct Nektar Therapeutics' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Nektar Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nektar Therapeutics' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Nektar Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Nektar Therapeutics' revenue streams: Identify Nektar Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Nektar Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Nektar Therapeutics' growth potential: Evaluate Nektar Therapeutics' management, business model, and growth potential.
  • Determine Nektar Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nektar Therapeutics' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.
When determining whether Nektar Therapeutics is a strong investment it is important to analyze Nektar Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nektar Therapeutics' future performance. For an informed investment choice regarding Nektar Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Nektar Stock please use our How to Invest in Nektar Therapeutics guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Nektar Stock analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.